Format

Send to

Choose Destination
Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480.

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

Author information

1
Division of Medical Oncology 2, "Regina Elena" National Cancer Institute, Rome, Italy.
2
Biostatistics Unit, "Regina Elena" National Cancer Institute, Rome, Italy.
3
Division of Oncology, S. Anna Hospital, Ferrara, Italy.
4
Department of Experimental and Clinical Sciences, University "G. d'Annunzio", Chieti, Italy.
5
Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
6
Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Oncology Unit, Istituto Chirurgico Ortopedico Traumatologico, Latina, Italy.
7
Oncology Unit I, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
8
Department of Oncology, Division of Medical Oncology, Belcolle Hospital, ASL Viterbo, Viterbo, Italy.
9
Department of Oncology, Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy.
10
Department of Medical Oncology, S. Luca Hospital, Lucca, Italy.
11
Division of Medical Oncology, IRCCS, Giovanni Paolo II Hospital, Bari, Italy.
12
Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
13
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
14
Medical Oncology, Ospedale San Giovanni Calibita Fatebenefratelli, Rome, Italy.
15
Oncology Unit, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
16
Medical Oncology, S. Spirito Hospital, Rome, Italy.
17
Scientific Direction, "Regina Elena" National Cancer Institute, Rome, Italy.
18
Department of Molecular Medicine, "Umberto I", "Sapienza" University of Rome, Roma, Italy.
19
Investigative Clinical Oncology, Fondazione del Piemonte per l'Oncologia-Candiolo Cancer Institute (IRCCs), Candiolo, Italy.
20
Division of Medical Oncology, Ospedale Civile di Saluzzo, Saluzzo, Italy.

Abstract

We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identified 872 TP BC pts treated with adjuvant chemotherapy alone (cohort A-366 pts), or plus trastuzumab (cohort B-506 pts). Relapse-free-survival (RFS) and breast-cancer-specific-survival (BCSS) were evaluated. Trastuzumab improved RFS and BCSS in all the subsets analyzed, but the effect on BCSS in tumors expressing both HRs in >30% of cells (TP30), and even on RFS in tumors with both HRs expressed in >50% of cells (TP50) was not significant. Distinct patterns of relapse were observed in TP50 and no-TP50 tumors, the former showing low and constant risk in the first 5 years, a late increase beyond 5 years and modest trastuzumab effect. Trastuzumab effect tended to disappear in pts whose tumors expressed ER in >50% of cells. Multivariate analysis of RFS confirmed a significant interaction between trastuzumab and ER expression, with benefit confined to pts whose tumors expressed ER in ≤50% of cells. Our data suggest that the pattern of relapse of TP tumors with high HRs is similar to that of "luminal", HER2 negative tumors, without clear benefit from adjuvant trastuzumab, which remains the standard treatment even in TP tumors. Confirmatory findings on the extent to which quantitative expression of HRs may impact clinical behavior of HER2 positive BC are warranted.

KEYWORDS:

adjuvant breast cancer; chemotherapy; hormonal receptors; trastuzumab; triple positive

PMID:
26910921
PMCID:
PMC4951261
DOI:
10.18632/oncotarget.7480
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center